BB Biotech AG : Q2 2021 portfolio update: Target price lifted to € 82
>Positive momentum maintained in Q2 - BB Biotech published its Q2 2021 results on Friday, 23 July. The positive earnings trend recorded at the beginning of the year was maintained in Q2, mirroring the sector recovery recorded over the period (NBI up 8% vs -0.5% in Q1), with a price increase of 5.8% in Swiss francs and 6.1% in euros. The portfolio grew by 3.3%, 4.2% and 5.3% in Swiss francs, euros and US dollars respectively, resulting in a net gain of CHF 128m (vs CHF...Co.'s principal activity is to invest in biotechnology companies globally. The investments are held through its wholly-owned subsidiaries: Biotech Focus N.V., Biotech Invest N.V., Biotech Target N.V., and Biotech Growth N.V., all of which are located in Curacao. Co. acquires holdings in companies in the biotechnology growth market. The focus of the holdings is on quoted companies that are concentrating on the development and marketing of innovative medicines. For the selection of holdings, Co. relies on fundamental analysis by physicians and molecular biologists.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.